Reply to letter by Isenberg and Gordon commenting on the Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus

Authors


Reply to Letter by Isenberg and Gordon Commenting on the Pediatric Rheumatology International Trials Organization Criteria for the Evaluation of Response to Therapy in Juvenile Systemic Lupus Erythematosus

To the Editor:

We thank Drs Isenberg and Gordon (1) for their interest in our article (2), which reports the first part of a 2-phase study devoted to the validation of a core set of disease activity measures for juvenile-onset systemic lupus erythematosus (SLE) and to the development of a preliminary definition of improvement to be used in clinical trials of juvenile-onset SLE. We used the SLE Disease Activity Index (3), the Systemic Lupus Activity Measure (4), and the European Consensus Lupus Activity Measure (5) as global activity measures because they were chosen by the pediatric rheumatologists who participated in the consensus conference in which the preliminary core set of disease activity measures was selected (6). As we state in the companion article (7), which presents the preliminary definition of improvement, investigators are free to use the global activity index that they deem most appropriate for clinical trial purposes.

Nicolino Ruperto MD, MPH*, Angelo Ravelli MD*, Irccs G. Gaslini*, Alberto Martini MD*, Irccs G. Gaslini*, * Università degli Studi, Genoa, Italy for the Pediatric Rheumatology, International Trials Organization (PRINTO).

Ancillary